Coherus Oncology (CHRS) Operating Income Growth (3y) (2016 - 2026)

Coherus Oncology (CHRS) Operating Income Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Oculis Holding AG 68,725.60 Bn 68,725.31 Bn - 16.96%
2 Nanobiotix 1,953.19 Bn 1,953.13 Bn - -
3 Akari Therapeutics 1,132.35 Bn 1,132.35 Bn - -
4 BeOne Medicines 472.73 Bn 467.94 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 123.52 Bn 116.27 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 69.74 Bn 60.99 Bn 3.31 Bn -12.10%
7 Belite Bio 63.09 Bn 63.09 Bn - -
8 Argenx Se 56.42 Bn 51.24 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.76 Bn 37.76 Bn - -
10 Coherus Oncology 201.19 Mn 34.14 Mn 8.50 Mn 18.89%

Historic Data

Download Data
DateValue
Mar 31, 2026 18.89%
Dec 31, 2025 3.77%
Sep 30, 2025 18.01%
Jun 30, 2025 -1.10%
Mar 31, 2025 17.50%
Dec 31, 2024 -4.70%
Sep 30, 2024 -12.64%
Jun 30, 2024 -17.92%
Mar 31, 2024 26.01%
Dec 31, 2023 -83.66%
Sep 30, 2023 -43.41%
Jun 30, 2023 -36.24%
Mar 31, 2023 -54.08%
Dec 31, 2022 -46.49%
Sep 30, 2022 -52.58%
Jun 30, 2022 -53.27%
Mar 31, 2022 -69.56%
Dec 31, 2021 13.21%
Sep 30, 2021 16.82%
Jun 30, 2021 18.67%